【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding the disease
• Etiology
• Signs and symptoms
• Diagnosis
• Management
• Economic burden
• Epidemiology
PART 06: Pipeline portfolio
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of disease
• RA
• MS
• PsA
• IBD
• AS
• SLE
• Global RA drugs market
• Clinical trials for RA
• Global MS drugs market
• Global PsA drugs market
• Global IBD drugs market
• Global AS drugs market
• Global SLE drugs market
PART 09: Market segmentation by mechanism of action
• TNF inhibitors
• IL-1 blockers
• COX inhibitors
• PDE4 inhibitors
• Others
PART 10: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Immunosuppressants
• Others
PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules
PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical
PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid
PART 14: Geographical segmentation
• Autoimmune diseases drugs market in the Americas
• Autoimmune diseases drugs market in US
• Autoimmune diseases drugs market in EMEA
• Autoimmune diseases drugs market in APAC
• Autoimmune diseases drugs market in Japan
• Autoimmune diseases drugs market in China
PART 15: Market drivers
• Rising prevalence of autoimmune diseases
• Growing older population
• Dominance of biologics
• Unmet medical needs
• Promising pipeline
PART 16: Impact of drivers
PART 17: Market challenges
• Increasing cost of biologics
• Loss of patent exclusivity of branded therapies
• Complex nature of autoimmune diseases
• Preference for CAMs
• Adverse effects
PART 18: Impact of drivers and challenges
PART 19: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Increase in public awareness programs
• Strategic alliances
• Popularity of off-label and traditional treatment options
PART 20: Vendor landscape
• Competitive scenario
• Market analysis 2015
• AbbVie
• Johnson & Johnson
• Biogen
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Other prominent vendors
PART 21: Appendix
• List of abbreviations
PART 22: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Etiology of autoimmune diseases
Exhibit 03: Signs and symptoms of autoimmune diseases
Exhibit 04: Diagnostic methods for autoimmune diseases
Exhibit 05: Non-pharmacological therapies used for autoimmune diseases
Exhibit 06: Pharmacotherapy therapies used for autoimmune diseases
Exhibit 07: Top drugs for autoimmune diseases
Exhibit 08: Average annual treatment costs of RA in US and Europe 2014 ($ billions)
Exhibit 09: Average annual treatment costs of MS across countries 2014 ($ billions)
Exhibit 10: Average annual treatment costs of PsA across countries 2014 ($ billions)
Exhibit 11: Prevalence and incidence of SLE
Exhibit 12: Pipeline molecules for RA
Exhibit 13: Pipeline molecules for MS
Exhibit 14: Pipeline molecules for PsA
Exhibit 15: Pipeline molecules for CD
Exhibit 16: Pipeline molecules for UC
Exhibit 17: Pipeline molecules for SLE
Exhibit 18: Global autoimmune diseases drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Global autoimmune diseases drugs market segmentation by type of disease
Exhibit 21: Global autoimmune diseases drugs market by type of disease 2015
Exhibit 22: Global autoimmune diseases drugs market: YoY revenue and growth based on autoimmune diseases 2015-2020
Exhibit 23: Global RA drugs market 2015-2020 ($ billions)
Exhibit 24: Global RA drugs market by drug class 2015
Exhibit 25: Top-vendor offerings for global RA drugs market
Exhibit 26: RA clinical trial by Phase 2015
Exhibit 27: RA clinical trial by status 2015
Exhibit 28: Drivers and challenges of global RA drugs market
Exhibit 29: Global MS drugs market 2015-2020 ($ billions)
Exhibit 30: Global MS drugs market by molecule type 2015
Exhibit 31: Top-vendor offerings for global MS drugs market
Exhibit 32: Drivers and challenges of global MS drugs market
Exhibit 33: Global PsA drugs market 2015-2020 ($ billions)
Exhibit 34: Global PsA drugs market segmentation by MOA 2015
Exhibit 35: Top-vendor offerings for global PsA drugs market
Exhibit 36: Drivers and challenges of global PsA drugs market
Exhibit 37: Global IBD drugs market 2015-2020 ($ billions)
Exhibit 38: Global IBD drugs market by type of disease 2015
Exhibit 39: Global IBD drugs market by drug class 2015
Exhibit 40: Top-vendor offerings for global IBD drugs market
Exhibit 41: Drivers and challenges of global IBD drugs market
Exhibit 42: Global AS drugs market 2015-2020 ($ billions)
Exhibit 43: Global AS drugs market by MOA 2015
Exhibit 44: Top-vendor offerings for global AS drugs market
Exhibit 45: Drivers and challenges of global AS drugs market
Exhibit 46: Global SLE drugs market 2015-2020 ($ billions)
Exhibit 47: Drivers and challenges of global SLE drugs market
Exhibit 48: Global autoimmune diseases drugs market segmentation by MOA
Exhibit 49: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 50: Global autoimmune diseases drugs market share by MOA 2015
Exhibit 51: Global autoimmune diseases drugs market segmentation by drug class
Exhibit 52: Examples of non-biologic DMARDs and biologic DMARDs for autoimmune diseases
Exhibit 53: NSAIDs used to treat autoimmune diseases
Exhibit 54: Global autoimmune diseases drugs market by drug class 2015
Exhibit 55: Global autoimmune diseases drugs market segmentation by type of molecule
Exhibit 56: Global autoimmune diseases biologics market 2015-2020 ($ billions)
Exhibit 57: Global autoimmune diseases small molecules market 2015-2020 ($ billions)
Exhibit 58: Global autoimmune diseases drugs market by type of molecules 2015
Exhibit 59: Global autoimmune diseases drugs market segmentation by ROA
Exhibit 60: Global autoimmune diseases drugs market segmentation by ROA 2015
Exhibit 61: Global autoimmune diseases drugs market segmentation by dosage form
Exhibit 62: Global autoimmune disease drugs market segmentation by dosage form 2015
Exhibit 63: Global autoimmune diseases drugs market segmentation by geography 2015
Exhibit 64: Global autoimmune diseases drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 65: Autoimmune diseases drugs market in the Americas 2015-2020 ($ billions)
Exhibit 66: Autoimmune diseases drugs market in America by country 2015
Exhibit 67: Autoimmune diseases drugs market in US 2015-2020 ($ billions)
Exhibit 68: Drivers and challenges for autoimmune diseases drugs market in the US
Exhibit 69: Autoimmune diseases drugs market in EMEA 2015-2020 ($ billions)
Exhibit 70: Autoimmune diseases drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: Autoimmune diseases drugs market in Japan 2015-2020 ($ billions)
Exhibit 72: Drivers and challenges for autoimmune diseases drugs market in Japan
Exhibit 73: Autoimmune diseases drugs market in China 2015-2020 ($ billions)
Exhibit 74: Global autoimmune diseases drugs market YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 75: Population aged 60 years and over ($ millions)
Exhibit 76: Biologics approval timeline by US FDA
Exhibit 77: Some pipeline molecules under phases of development for autoimmune diseases
Exhibit 78: Impact of drivers
Exhibit 79: Average annual treatment cost of adalimumab, etanercept, and infliximab 2014 ($ millions)
Exhibit 80: Approval and patent expiries of top selling biologics
Exhibit 81: CAM therapies for autoimmune diseases
Exhibit 82: Usage of CAM therapies among individuals in US 2014
Exhibit 83: Adverse effects associated with autoimmune disease therapies
Exhibit 84: Impact of drivers and challenges
Exhibit 85: Patient assistance programs for autoimmune diseases drugs
Exhibit 86: Revenue share of major companies for autoimmune diseases 2015
Exhibit 87: YoY Sales comparison of top drugs 2013-2015 ($ billions)
Exhibit 88: AbbVie: Product segmentation by revenue 20150
Exhibit 89: AbbVie: YoY growth rate and revenue of HUMIRA 2013-2015 ($ billions)
Exhibit 90: AbbVie: YoY growth rate and revenue of HUMIRA in US 2013-2015 ($ billions)
Exhibit 91: AbbVie: YoY growth rate and revenue of HUMIRA in ROW 2013-2015 ($ billions)
Exhibit 92: Sales of HUMIRA in major markets
Exhibit 93: AbbVie: Key takeaways
Exhibit 94: Johnson & Johnson: Segmentation of key autoimmune diseases drugs 2014
Exhibit 95: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2014 ($ billions)
Exhibit 96: Johnson & Johnson: YoY growth rate and revenue of Remicade in US 2013-2015 ($ billions)
Exhibit 97: Johnson & Johnson: YoY growth rate and revenue of Remicade in ROW 2013-2015 ($ billions)
Exhibit 98: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 99: Johnson & Johnson: YoY growth rate and revenue of Stelara in US 2013-2015 ($ billions)
Exhibit 100: Johnson & Johnson: YoY growth rate and revenue of Stelara in ROW 2013-2015 ($ millions)
Exhibit 101: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 102: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in US 2013-2015 ($ millions)
Exhibit 103: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria in ROW 2013-2015 ($ millions)
Exhibit 104: Johnson & Johnson: Key takeaways
Exhibit 105: Biogen: Product segmentation of key autoimmune diseases drugs by revenue 2015
Exhibit 106: Top selling autoimmune diseases drugs
Exhibit 107: Biogen: YoY growth rate and revenue of Tecfidera 2013-2015 ($ billions)
Exhibit 108: Biogen: YoY growth rate and revenue of Avonex 2013-2015 ($ billions)
Exhibit 109: Biogen: YoY growth rate and revenue of Tysabri 2013-2015 ($ billions)
Exhibit 110: Biogen: YoY revenue of Plegridy 2014-2015 ($ millions)
Exhibit 111: Biogen: YoY growth rate and revenue of Fampyra 2013-2015 ($ millions)
Exhibit 112: Biogen: Key takeaways
Exhibit 113: Amgen: YoY growth rate and revenue of Enbrel in US and Canada 2013-2015 ($ billions)
Exhibit 114: Amgen: YoY growth rate and revenue of Enbrel in US 2013-2015 ($ billions)
Exhibit 115: Amgen: YoY growth rate and revenue of Enbrel in Canada 2013-2015 ($ millions)
Exhibit 116: Amgen: Key takeaways
Exhibit 117: Pfizer: Autoimmune diseases drugs product segmentation by revenue 2014
Exhibit 118: Top selling autoimmune diseases drugs
Exhibit 119: Pfizer: YoY growth rate and revenue of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 120: Pfizer: YoY growth rate and revenue of Celebrex 2013-2015 ($ billions)
Exhibit 121: Pfizer: YoY growth rate and revenue of Xeljanz 2012-2014 ($ millions)
Exhibit 122: Pfizer: Key takeaways
Exhibit 123: Top selling autoimmune diseases drugs
Exhibit 124: F. Hoffmann-La Roche: YoY growth rate and revenue of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 125: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 126: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 127: F. Hoffmann-La Roche: YoY growth rate and revenue of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)
Exhibit 128: F. Hoffmann-La Roche: Geographic segmentation of MabThera/Rituxan by revenue 2015
Exhibit 129: F. Hoffmann-La Roche: Key takeaways
【レポート販売概要】
■ タイトル：自己免疫疾患用薬の世界市場2016-2020■ 英文：Global Autoimmune Drugs Market 2016-2020
■ 発行日：2016年3月18日
■ 調査会社：Technavio
■ 商品コード：IRTNTR9055
■ 調査対象地域：グローバル
- 2014 Assessments of Leading Infectious Disease Market Players–Insightful Profiles of Major Suppliers and Emerging Market EntrantsThis new report from Venture Planning Group provides strategic assessments of major suppliers of infectious deisease instuments and reagants, as well as emerging market entrants. The report presents strategic assessments of leading market players and emerging suppliers with innovative technologies and products in terms of their sales, product portfolios, distribution tactics, technological know-ho …
- 半導体パッケージ材料の世界市場2015-2019About Semiconductor Packaging Materials Semiconductor packaging materials comprise metals, plastic, and ceramic components. They not only protect the IC on the semiconductor die, but also interconnect the die and the PCB. They protect the die from external mechanical impacts and corrosion, and also act as an electrically conductive interconnects with excellent signal propagation properties. Excess …
- マイクロブルワリー（地ビール醸造所）用装置の世界市場2017-2021About Microbrewery EquipmentMicrobrewery equipment refers to the set of equipment used to produce craft beer. Some of the major categories of microbrewery equipment are mashing systems, cooling systems, fermentation systems, controlling systems, and cleaning systems. The average lifespan of microbrewery equipment is four years. Most of the vendors offer the equipment along with warranty and good a …
- Vermilion Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Vermilion Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Vermilion Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source …
- 電動洗浄機の世界市場2016-2020Covering: This market research report covers the growth prospects of the global electric power washer market with segmentation based on end users (residential and commercial) and region (Americas, Europe, APAC, and ROW). It also includes an insightful analysis of the leading vendors in this market, including Simpson, Generac, Karcher, and Snowjoe. The growing interest of homeowners to spruce up ba …
- （製薬リーディング企業）CRO企業ベンチマークレポートPharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs Summary The CRO Benchmark Report applies GlobalData’s proprietary ranking methodology to compare the competitive positions of 11 leading CRO companies on 17 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure and …
- RF MEMSデバイスの世界市場About RF MEMS RF MEMS are components that are integrated in electronic systems and provide RF functionality. Some of the types of RF MEMS components include CMOS integrable RF MEMS resonators and self-sustained oscillators, RF MEMS tunable inductors, RF MEMS switches, switched capacitors, and varactors. MEMS devices employed in RF applications are called RF MEMS. The term RF MEMS signifies the des …
- サービスとしてのアクセスコントロール（ACaaS）の世界市場予測（～2022）：サービス別、導入別、最終用途別（商用、製造＆産業、政府機関、公共設備）、地域別The ACaaS market is expected to reach USD 1,678.3 Million by 2022, growing at a CAGR of 26.82% between 2016 and 2022. The key factor driving this market has been the increased demand for ACaaS from businesses with multiple locations to centralize their operations. Furthermore, the large-scale adoption of Internet of Things (IoT) and increased usage of advance virtualization and cloud computing pla …
- 世界のSSL証明書市場動向（2012-2016）TechNavio's analysts forecast the Global Secure Sockets Layer (SSL) Certification market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing number of online transactions. The Global SSL Certification market has also been witnessing the increasing adoption of SSL Certification by small and medium-sized enterprise …
- 時間計測器の世界市場2017-2021：発振器、半導体クロック、共振器ABSTRACTAbout Timing Devices Timing device products include quartz crystal devices and integrated circuits (ICs) as well as microelectromechanical system (MEMS) timing devices. Crystal oscillators are crucial in electronics design. However, this technology is being replaced with MEMS devices and CMOS oscillators. Other timing ICs include clock synthesizers, PLLs, clock distribution devices, and cl …
- バイオ技術投資レポート：プライベート・エクイティ及びベンチャーキャピタル投資動向PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding Summary GlobalData’s "PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding" report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry …
- バイオセンサーの世界市場：電気化学型バイオセンサー、圧電型バイオセンサー、光型バイオセンサー、熱型バイオセンサーThe biosensor is a device which is used for detecting, recording, and transmitting information related to any physiological changes or the presence of various chemicals or biological materials in the environment. In other words, we can say that it is an analytical device, which converts the biological response into electrical signals. The biosensors technology is now being used for the development …
- ダクトレス暖房＆冷却システムの世界市場予測：スプリットシステム、ウィンド形空調機The global ductless heating & cooling systems market is projected to reach USD 78.62 Billion by 2021, at a CAGR of 8.18% from 2016 to 2021. Ductless heating & cooling systems are experiencing a high demand from the construction sector in the Asia-Pacific region. Expansions and new product development activities related to the development more energy efficient solutions undertaken by different comp …
- AMI（高度メータリングインフラストラクチャ）の世界市場：スマートメーター、メーター通信インフラ（MCI）、メーターデータ管理（MDM）About AMI An AMI refers to an infrastructure ranging from smart meters to two-way communication networks through various communication and data processing channels. It comprises of all the applications that permit the assembly and flow of energy usage on real-time basis. It makes two-way communications with clients possible. It is considered as the backbone of the smart grid because all the operat …
- Mixed Dyslipidemia（脂質異常症）：グローバル臨床試験動向（2014年上半期）Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Mixed Dyslipidemia Global Clinical Trials Review, H1, 2014" provides data on the Mixed Dyslipidemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mixed Dyslipidemia. It includes an overview of the trial numbers and their recruitme …
